Trial Profile

A Single-Dose, Open-Label Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous administration of Fremanezumab in Pediatric Migraine Patients (6 to 11 Years of Age Inclusive)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 May 2021 Results of dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from this study published in the Cephalalgia
30 Jul 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com